Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Platelet aggregation disorders].

H Patscheke1

  • 1Zentrum für Labormedizin, Mikrobiologie und Transfusionsmedizin, Städtisches Klinikum, Moltkestrasse 90, 76133 Karlsruhe.

Hamostaseologie
|November 7, 2003
PubMed
Summary

Anticoagulants and GPIIb/IIIa antagonists interfere with final coagulation steps, increasing bleeding risk. Acetylsalicylic acid (ASA) and other platelet inhibitors target earlier activation, posing lower bleeding risks and not requiring drug monitoring.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Factor XII C46T gene polymorphism and the risk of cerebral venous thrombosis.

Neurology·2008
Same author

Platelet activation through triathlon competition in ultra-endurance trained athletes: impact of thrombin and plasmin generation and catecholamine release.

International journal of sports medicine·2001
Same author

Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.

Thrombosis and haemostasis·2000
Same author

Activation of blood platelets in response to maximal isometric exercise of the dominant arm.

International journal of sports medicine·2000
Same author

[Grand mal series after Ecstasy abuse].

Der Nervenarzt·2000
Same author

Exhaustive cycle exercise induces P-selectin expression, coagulation, and fibrinolysis activation in ultraendurance athletes.

Thrombosis research·1999

Area of Science:

  • Pharmacology
  • Hematology
  • Cardiovascular Medicine

Background:

  • Anticoagulants and platelet inhibitors are crucial for managing thrombotic events.
  • Different drug classes target distinct pathways in hemostasis and platelet aggregation.
  • Understanding these mechanisms is key to optimizing therapeutic strategies and managing bleeding risks.

Purpose of the Study:

  • To differentiate the mechanisms of action between anticoagulants and various platelet inhibitors.
  • To assess the bleeding risk associated with different classes of antithrombotic agents.
  • To evaluate the necessity and utility of therapeutic drug monitoring for these medications.

Main Methods:

  • Comparative analysis of anticoagulant and platelet inhibitor mechanisms.
  • Review of clinical study data on bleeding risk and therapeutic efficacy.
  • Discussion of diagnostic tools for monitoring drug levels and hemostatic function.

Main Results:

  • Anticoagulants and GPIIb/IIIa antagonists inhibit final common pathways, elevating bleeding risk.
  • Acetylsalicylic acid (ASA), clopidogrel, and ticlopidine inhibit platelet activation, with lower bleeding risks.
  • Parenteral GPIIb/IIIa antagonists are approved; oral forms show increased bleeding without sufficient benefit.
  • Therapeutic drug monitoring is generally not required for ASA, clopidogrel, or ticlopidine.

Conclusions:

  • Drug choice significantly impacts bleeding risk and the need for monitoring.
  • GPIIb/IIIa antagonists, particularly oral forms, require careful risk-benefit assessment.
  • Comprehensive evaluation of hemostatic factors is essential when using antithrombotics, especially in combination therapy.

Related Experiment Videos